How much does satlizumab (Anshiping) cost?

Satralizumab (Satralizumab) is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are positive for aquaporin-4 (AQ P4) antibodies. Satclizumab is a humanized monoclonal antibody directed against IL-6 receptor activity. The cytokine IL-6 is thought to be a key driver of NMOSD, triggering an inflammatory cascade and leading to damage and disability.

Positive Phase III results with satelizumab as monotherapy and concurrently with baseline immunosuppressant therapy suggest that IL-6 inhibition is an effective treatment for NMOSD. The Phase III clinical development program for satelizumab includes two studies: SAkuraStar and SAkuraSky. Satclizumab is also approved in Canada, Japan and Switzerland. Satclizumab has orphan drug designation in the United States, Europe and Japan. Additionally, it was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in December 2018 for the treatment of neuromyelitis optica spectrum disorder.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.